Zhaoke Ophthalmology Limited announced that the Company has entered into an exclusive license, supply and distribution agreement with Eyedetec Medical Inc. Under the terms of the Agreement, Eyedetec Medical grants Zhaoke Ophthalmology exclusive rights to register, import, promote, distribute, market and sell the Eye Lipid Mobilizer(TM), a medical device that is designed to treat DED, in Greater China (mainland China, Hong Kong, Macau and Taiwan), South Korea and the ASEAN countries (Brunei, Cambodia, Indonesia, Laos, Malaysia, Philippines, Singapore, Thailand and Vietnam). ELM is a proprietary medical device that is intended to treat moderate to severe DED by stabilizing the oil layer of the eye's tear film. The result is decreased tear evaporation and normalized ocular surface.

By uniquely combining several mechanisms, ELM delivers heat to the eyelids to lower the viscosity of the oil (i.e. meibum). Upon clearance in the U.S., ELM will become the first and only physician-pres prescribed therapy that treats the root cause of dry eye disease at home. Eyedetec Medical's clinical study conducted in the U.S. in February and March 2022 demonstrated compelling evidence of efficacy of the device, and a human factors study in March 2022 demonstrated that ELM is intuitive and easy for patients to learn and use.

ELM has already received high recognition from the industry, including winning second place for the Winning Pitch Challenge presentations at Eyecelerator 2023 during ASCRS (American Society of Cataract and Refractive Surgery) on May 4 in San Diego. Zhaoke Ophthalmology is strategically focused on treatments that cover both the front-and back-of-the-eye ophthalmic diseases, including DED. The company always strive to deliver the best treatment options with a combination of drugs and medical devices to patients.

This partnership has expanded medical device portfolio and enabled to cover a wider range of severity of DED patients in the region.